Calidi's CLD-401 shows high rates of complete tumor eradication in mice

• Calidi Biotherapeutics will present preclinical CLD-401 and T-cell engager platform data at the ESMO Congress on October 24, 2026.
• CLD-401 showed high rates of complete tumor eradication in mice bearing EMT6 breast cancer tumors.
• In an MB49 bladder cancer model, CLD-401 retained antitumor activity with either intravenous or intratumoral administration.
• RedTail-based candidates CLD-501 and CLD-502 demonstrated antigen-dependent, dose-responsive T-cell killing targeting TROP-2 and EpCAM, respectively.
• Adding a T-cell engager payload to the EpCAM-targeted construct did not reduce IL-15 superagonist expression in laboratory or animal studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847553) on October 19, 2026, and is solely responsible for the information contained therein.